Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDF2 | Q9Y5A9 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21220415 | 0.90 | MAPK1 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL6749028 | 0.90 | MAPK1 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL2926149 | 0.90 | SLC6A2 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL9115684 | 0.88 | KMT2A (0.33) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL12243196 | 0.83 | — | — | |
| SCHEMBL6779505 | 0.79 | — | — | |
| SCHEMBL24663384 | 0.77 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL10659466 | 0.77 | SLC6A2 (0.37) | PLG | |
| SCHEMBL6750420 | 0.77 | DRD2 (0.41) | — | |
| SCHEMBL10635856 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119522227-A | Macrocyclic compounds, pharmaceutical compositions and uses thereof | 贝达药业股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-117460732-A | Pyrrolopyridone compounds, preparation method and application thereof | 杭州中美华东制药有限公司 | 2024-01-26 | — | — | CN | disclosed |
| WO-2024017358-A1 | MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 贝达药业股份有限公司 | 2024-01-25 | — | — | WO | disclosed |
| US-8461340-B2 | Method for producing cis-3-substituted-3-azabicyclo[3.2.1]octan-8-ol derivative | NIPPON SODA CO., LTD. (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8431707-B2 | Process for production of azabicycloalkanol derivative | NIPPON SODA CO., LTD. (JP) | 2013-04-30 | — | — | US | disclosed |
| US-20120209004-A1 | PROCESS FOR PRODUCTION OF AZABICYCLOALKANOL DERIVATIVE | NIPPON SODA CO. LTD. | 2012-08-16 | — | — | US | disclosed |
| US-8188286-B2 | Process for production of azabicycloalkanol derivative | NIPPON SODA CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| EP-2184274-B1 | PROCESS FOR PRODUCTION OF CIS-3-SUBSTITUTED-3- AZABICYCLO[3.2.1]OCTAN-8-OL DERIVATIVE | NIPPON SODA CO (JP) | 2012-04-18 | — | — | EP | disclosed |
| EP-2080755-B1 | PROCESS FOR PRODUCTION OF AZABICYCLOALKANOL DERIVATIVE | NIPPON SODA CO (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20100286398-A1 | METHOD FOR PRODUCING CIS-3-SUBSTITUTED-3-AZABICYCLO[3.2.1]OCTAN-8-OL DERIVATIVE | NIPPON SODA CO., LTD. (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2184274-A1 | PROCESS FOR PRODUCTION OF CIS-3-SUBSTITUTED-3- AZABICYCLO[3.2.1]OCTAN-8-OL DERIVATIVE | Nippon Soda Co., Ltd. (JP) | 2010-05-12 | — | — | EP | disclosed |
| US-20090259045-A1 | Process for production of azabicycloalkanol derivative | NIPPON SODA CO., LTD. (JP) | 2009-10-15 | — | — | US | disclosed |
| EP-2080755-A1 | PROCESS FOR PRODUCTION OF AZABICYCLOALKANOL DERIVATIVE | Nippon Soda Co., Ltd. (JP) | 2009-07-22 | — | — | EP | disclosed |
| US-6699870-B2 | Phthalazine compounds and therapeutic agents for erectile dysfunction | EISAI CO., LTD. (JP) | 2004-03-02 | — | — | US | disclosed |
| US-20030105074-A1 | Phthalazine compounds and therapeutic agents for erectile dysfunction | EISAI CO., LTD. | 2003-06-05 | — | — | US | disclosed |
| US-6498159-B1 | SUCH AS 4-((3-CHLORO-4-METHOXYBENZYL)AMINO)-1-((4-HYDROXY-4 -HYDROXYMETHYL)PIPERIDINO)-6-PHTHALAZINE CARBONITRILE | EISAI CO., LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| EP-1057819-A1 | PHTHALAZINE DERIVATIVES AND REMEDIES FOR ERECTILE DYSFUNCTION | Eisai Co., Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| US-4719217-A | Certain N-azabicycloalkyl-benzamides useful in the treatment of impaired gastro-intestinal motility or emesis | BEECHAM GROUP P.L.C. (GB) | 1988-01-12 | — | — | US | disclosed |
| EP-0212802-A1 | Substituted benzamides | BEECHAM GROUP PLC (GB) | 1987-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286398-A1 | METHOD FOR PRODUCING CIS-3-SUBSTITUTED-3-AZABICYCLO[3.2.1]OCTAN-8-OL DERIVATIVE | OXER1, OR10J3, ALOX12 | YTHDF2 2732/4885CHRNB2 1334/4885CHRNB4 1898/4885 |
| US-20090259045-A1 | Process for production of azabicycloalkanol derivative | CYP8B1, CYP3A43, OR10J3 | YTHDF2 1664/4885CHRNB2 1305/4885CHRNB4 1688/4885 |
| US-20120209004-A1 | PROCESS FOR PRODUCTION OF AZABICYCLOALKANOL DERIVATIVE | CYP8B1, CYP3A43, OR10J3 | YTHDF2 1664/4885CHRNB2 1305/4885CHRNB4 1688/4885 |
| US-20030105074-A1 | Phthalazine compounds and therapeutic agents for erectile dysfunction | CLIC1, CBR1, CBR3 | YTHDF2 2981/4885CHRNB2 522/4885CHRNB4 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.